Lemaitre Vascular (LMAT) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We face competition from other medical device companies and alternative medical technologies, and we may not be able to compete effectively
2. 02may obtain patent protection or regulatory approval or clearance, or achieve product commercialization, before us
3. 03If we are unable to source, acquire and integrate new businesses, product lines, or technologies, we may not achieve our growth objectives and our results of operations could suffer
4. 04dilution as a result of equity financing or the incurrence of additional debt required to fund acquisition costs
5. 05If we are unable to increase our selling prices to customers, or if we are required to make price concessions, our sales growth could be reduced and our operating results could suffer
6. 06certain marketplace changes, such as hospitals joining group purchasing organizations, integrated delivery networks, and managed care organizations
7. 07We may not be able to maintain our historic levels of profit growth
8. 08Our dependence on sole- and limited-source suppliers could hinder our ability to deliver our products and services to our customers and could harm our results of operations
9. 09We may experience challenges with the ongoing implementation of our new enterprise resource planning system
10. 10Significant disruptions of information technology systems or breaches of information security systems could adversely affect our business
11. 11Some of our devices are sold to a different call point, and we may not be successful in selling to that newer call point
12. 12Our tissue processing and preservation services are subject to a variety of risks, including those related to the procurement of human tissue and regulatory requirements
13. 13compliance of our tissue procurement organizations to current good tissue practices
14. 14Any disruption in our manufacturing facilities could harm our results of operations
15. 15The risks inherent in operating internationally and the risks of selling and shipping our products and of purchasing our components and products internationally may adversely impact our net sales, results of operations, and financial condition
16. 16We may experience disruptions to our international business to the extent we transition our sales strategy in certain international jurisdictions from a distributor-based approach to a direct sales model
17. 17The use or misuse of our products and the tissues we distribute may result in injuries that lead to product liability lawsuits or legal actions, which could be costly to our business
18. 18From time to time, we are involved in litigation where the outcome is uncertain and which could entail significant expense

Risks Related to the Regulatory Environment

1. 19Our business is subject to complex, costly, and burdensome regulations. We could be subject to significant penalties if we fail to comply
2. 20If we are not successful in obtaining additional and maintaining current clearances and approvals from U.S. governmental agencies for our medical devices, we might not be able to sell our products, and our future growth might be hampered
3. 21If we or some of our suppliers fail to comply with the FDA’s QSR and other applicable requirements, our manufacturing or processing operations could be disrupted, and we may become subject to a variety of FDA enforcement actions
4. 22If we do not comply with international regulatory requirements to market our products or if we need to modify our operations or products as a result of such requirements, our business may be harmed
5. 23Oversight of the medical device industry might affect the manner in which we may sell medical devices and compete in the marketplace
6. 24Certain of our products contain materials derived from animal sources and may become subject to additional regulation
7. 25Certain of our products are manufactured, packaged, or sterilized using chemicals or substances that have drawn environmental concern. To the extent that the use of such chemicals or substances is restricted or banned, options to replace such chemicals or substitutes may not be readily available to us
8. 26Our human tissue cryopreservation services are subject to a wide variety of federal, state, and international regulations, and our failure to comply would impair our ability to operate in that space and negatively affect our operating results

Risks Related to Our Debt

1. 27Servicing our 2.50% convertible senior notes requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt
2. 28We may not have the ability to raise the funds necessary to repurchase the Convertible Notes as required upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Convertible Notes
3. 29The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our liquidity
4. 30Transactions relating to the Convertible Notes may affect the value of our common stock

Risks Related to Human Resources

1. 31If we are not able to navigate executive officer transitions and retain key personnel, our business may be harmed
2. 32Employee equity awards may provide less of an employee retention benefit if the price of our common stock is unable to grow beyond the record highs it has recently achieved

Risks Related to Intellectual Property

1. 33If we fail to adequately protect our intellectual property rights, or prevent use of our intellectual property by third parties, we could lose a significant competitive advantage and our business may suffer
2. 34If third parties claim that we infringe upon their intellectual property rights, we may incur liabilities and costs, and we may have to redesign or discontinue selling the affected product
3. 35result in our customers or potential customers deferring or limiting their purchase or use of the affected products until resolution of the litigation

Risks Related to Our Common Stock

1. 36Our stock price may be volatile, and an investment in our common stock could suffer a decline in value
2. 37our inclusion in or removal from stock market indices, such as the S&P 600 or Russell 2000
3. 38Our Chief Executive Officer has significant voting power and may take actions that may not align with the interests of our other stockholders
4. 39We have not established a minimum dividend payment level for our common stockholders and there are no assurances of our ability to pay dividends to common stockholders in the future